Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas
- 6 July 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 173 (2) , 527-534
Abstract
Refractory locally advanced or metastatic nonmelanoma skin cancer (NMSC) is a frequent therapeutic impasse. To address the question of the efficacy of induction therapy with cetuximab as neoadjuvant treatment for locally advanced NMSC. From 2008 to 2013, all patients with a diagnosis of unresectable locally advanced skin squamous cell carcinoma were treated with neoadjuvant cetuximab alone (CM) or combined with a platinum salt and 5-fluorouracil (CC). Resectability, and clinical and pathological response, as well as relapse-free and overall survival were evaluated. Thirty-four patients, with a median age of 74·5 years, were evaluated. Twenty-five patients received CC. After three cycles of CC, 23 of 25 patients whose tumours were initially unresectable became amenable to surgery (92%). A complete histological response was observed in 15 (65%) patients. The mean progression-free and mean overall survival in operated patients were 8·5 and 26·0 months, respectively. There was a good response in terms of resectability and tumour control in the majority of patients, with few relapses, despite the initially poor prognosis of these tumours in this elderly group of patients. However, this therapeutic strategy needs to be validated in a prospective, randomized study.Keywords
This publication has 18 references indexed in Scilit:
- Efficacy of Cetuximab for Unresectable or Advanced Cutaneous Squamous Cell Carcinoma — A Report of Eight CasesClinical Oncology, 2011
- Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the SkinJournal of Clinical Oncology, 2011
- Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME studyAnnals of Oncology, 2010
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Cutaneous squamous cell carcinoma responding serially to single-agent cetuximabAnti-Cancer Drugs, 2007
- Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2006
- Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2005
- Cutaneous Squamous-Cell CarcinomaNew England Journal of Medicine, 2001
- Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skinCancer, 1991
- Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycinCancer, 1990